Highlights and Quick Summary
- Selling, General and Administrative (SG&A) Expenses Growth for the quarter ending September 29, 2021 was 7.82% (a -160.62% decrease compared to previous quarter)
- Year-over-year quarterly Selling, General and Administrative (SG&A) Expenses Growth decreased by -86.78%
- Annual Selling, General and Administrative (SG&A) Expenses Growth for 2020 was 47.33% (a -658.8% decrease from previous year)
- Annual Selling, General and Administrative (SG&A) Expenses Growth for 2019 was -8.47% (a -133.19% decrease from previous year)
- Annual Selling, General and Administrative (SG&A) Expenses Growth for 2018 was 25.52% (a 4016.13% increase from previous year)
- Twelve month Selling, General and Administrative (SG&A) Expenses Growth ending September 29, 2021 was 19.71% (a -38.56% decrease compared to previous quarter)
- Twelve month trailing Selling, General and Administrative (SG&A) Expenses Growth decreased by -66.9% year-over-year
Trailing Selling, General and Administrative (SG&A) Expenses Growth for the last four month:
| 29 Sep '21 | 29 Jun '21 | 30 Mar '21 | 30 Dec '20 |
|---|---|---|---|
| 19.71% | 32.08% | 74.18% | 59.55% |
Visit stockrow.com/ABBV
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Selling, General and Administrative (SG&A) Expenses Growth of AbbVie Inc.
Most recent Selling, General and Administrative (SG&A) Expenses Growthof ABBV including historical data for past 10 years.Interactive Chart of Selling, General and Administrative (SG&A) Expenses Growth of AbbVie Inc.
AbbVie Inc. Selling, General and Administrative (SG&A) Expenses Growth for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2021 | 7.82% | -12.9% | 61.47% | – | – |
| 2020 | 59.15% | 65.9% | 113.24% | 0.89% | 47.33% |
| 2019 | 1.14% | -13.65% | -6.02% | -6.2% | -8.47% |
| 2018 | -1.38% | 31.71% | 16.63% | 30.44% | 25.52% |
| 2017 | 16.5% | 5.5% | 2.93% | 1.33% | 0.62% |
| 2016 | -3.34% | -6.31% | -13.92% | -8.01% | -9.14% |
| 2015 | -48.01% | -7.59% | 17.61% | 9.93% | -17.31% |
| 2014 | 130.73% | 26.49% | 2.99% | 8.33% | 44.32% |
| 2013 | 2.62% | 16.22% | 12.84% | -0.8% | 7.28% |
| 2012 | – | – | -70.08% | -7.89% | -15.35% |
| 2011 | – | – | – | – | 54.29% |
| 2010 | – | – | – | – | 14.08% |
Business Profile of AbbVie Inc.
Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.